---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-344577"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2026-08-11T20:05:17+00:00"
generated_at: "2026-08-11T20:07:58.162559+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Immunome Q2 net loss $73.1M; FDA accepts varegacestat NDA, PDUFA April 28, 2027

## Summary
- FDA accepted NDA for varegacestat in desmoid tumors; PDUFA target April 28, 2027.
- Phase 3 RINGSIDE: 84% risk reduction (HR=0.16, p<0.0001); ORR 56% vs 9%.
- Cash $520.0M as of June 30, 2026; expected to fund operations into 2028.
- Q2 net loss $73.1M; R&D $59.9M, G&A $18.3M including stock comp.
- First patients dosed in Phase 1 trials of IM-1617 (June 2026) and IM-3050 (July 2026).

## SEC filing metadata
- accession: 0001193125-26-344577
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2026-08-11T20:05:17+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000119312526344577/0001193125-26-344577-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000119312526344577/imnm-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-344577
- JSON: https://secwatch.observer/filing/0001193125-26-344577.json
- Plain text: https://secwatch.observer/filing/0001193125-26-344577.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.